Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCaP Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
NCT01916109Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2013
- Primary completion
- Jul 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in bladder cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2013; status: terminated.
02
Drugs
panitumumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT01916109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01916109.